Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – PsiOxus

Executive Interview – PsiOxus

PsiOxus Therapeutics is an Oxford-based immunotherapy company that has developed a tumour-targeted delivery platform based on its lead oncolytic vaccine, Enadenotucirev (formerly ColoAd1). Enadenotucirev is an oncolytic virus that selectively kills cancer cells by lysis and is currently being studied in four clinical trials in various cancer indications. Under the PsiOxus collaboration with Bristol Myers Squibb, a Phase I combination study of Enadenotucirev with checkpoint inhibitor nivolumab (Opdivo) in a range of tumours, is due to start in Q316. PsiOxus also has a next-generation platform (T-SIGn Therapy) in development. This platform enables the anti-tumour effect of Enadenotucirev to be expanded through the addition of new genes (‘Armed EnAd’) creating a broad range of unique oncolytic immune therapeutics. NG-348, the first product candidate to emerge from this platform, will start Phase I in 2017.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

TMT

VEON – executive interview with CFO Joop Brakenhoff

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free